Exercise Intolerance and Skeletal Muscle Bioenergetics in Children With Deep Venous Thrombosis

Sponsor
University of Texas Southwestern Medical Center (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04294849
Collaborator
(none)
30
1
1
40.7
0.7

Study Details

Study Description

Brief Summary

This is a prospective cohort study of 30 patients who are 8-21 years of age with venous thromboembolism (VTE)- either lower extremity deep venous thrombosis (DVT) or pulmonary embolism (PE).

Condition or Disease Intervention/Treatment Phase
  • Other: Magnetic Resonance Imaging
  • Other: Bicycle Ergometry
  • Other: Lab Panel
  • Behavioral: Questionnaires
N/A

Detailed Description

Participants will be in three groups- those with lower extremity DVT, those with PE, or those with both lower extremity DVT and PE. Patients will have blood drawn for thrombin generation assay, thromboelastography assay, and thromboinflammatory panel in addition to standard of care labs for diagnosis of VTE and management of anticoagulation. The patients will then fill out questionnaires on quality of life and level of exercise at their first outpatient visit 4 weeks after diagnosis. At approximately 3-6 months after diagnosis, patients will undergo two days of testing for the research study. All patients will have exercise testing using bicycle ergometry to measure global aerobic fitness. They will once again fill out questionnaires about their quality of life and level of physical activity. After a 24 hour rest period, DVT patients will undergo 31P-MR Spectroscopy and non-invasive spin labeling MRI to provide data on skeletal muscle bioenergetics (phosphocreatine metabolism), and lymphatic and venous flow respectively in the affected leg compared to the unaffected leg. This will allow each patient to be his or her own control. After these research procedures, patients will continue to receive standard of care treatment for their VTE in the Bleeding and Thrombosis clinic.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Exercise Intolerance and Skeletal Muscle Bioenergetics in Children With Deep Venous Thrombosis
Actual Study Start Date :
Feb 6, 2020
Anticipated Primary Completion Date :
Jun 30, 2023
Anticipated Study Completion Date :
Jun 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Venous Thromboembolism Arm

This will be a cohort of patients age 8- ≤ 21 years old with objectively diagnosed DVT and/or PE.

Other: Magnetic Resonance Imaging
A. Phosphorous 31 MR Spectroscopy to evaluate skeletal muscle metabolism via measurement of depletion and recovery of phosphocreatine (PCr) B. Non-invasive arterial spin labeling MRI to evaluate lymphatic flow velocities and venous flow

Other: Bicycle Ergometry
To measure peak VO2 as a representation of global aerobic fitness

Other: Lab Panel
A. Inflammatory lab panel (IL-6, IL-8, TNF alpha, P-selectin, high sensitivity CRP, IL-6 receptor, TNF R1/R2) drawn at diagnosis B. Thrombin Generation Assay to measure hypercoagulability and Thromboelastography prior to initiating anticoagulation

Behavioral: Questionnaires
A. Dalhousie Dyspnea Scale B. Godin Leisure Time Exercise Questionnaire C. Pediatric Venous Quality of Life Questionnaire

Outcome Measures

Primary Outcome Measures

  1. Phosphocreatine Depletion and Recovery [31P MR Spectroscopy will be performed one time between 3-6 months after diagnosis.]

    Phosphocreatine (PCr) will be measured at baseline, during performance of submaximal exercise to fatigue and then at rest in the 31 P MR Spectroscopy Scan.

  2. Assessment for Venous Occlusion [Arterial Spin labeling MRI will be performed one time between 3-6 months after diagnosis.]

    Arterial spin labeling MRI will be utilized to examine venous flow in bilateral lower extremities to assess for venous occlusion.

  3. Assessment of Lymphatic flow [Arterial Spin labeling MRI will be performed one time between 3-6 months after diagnosis]

    Arterial spin labeling MRI will be utilized to assess lymphatic flow in bilateral lower extremities to assess for adequate lymphatic drainage.

  4. Inflammatory markers [Diagnosis to 4 weeks.]

    A custom blood assay will be used to assess inflammation at the time of the thrombotic event. Assay will include measurements of IL-6, IL-8, TNF-alpha, CRP, IL-10, IL-6 receptor, TNF alpha receptors.

  5. Coagulation markers [Diagnosis to 4 weeks.]

    Thrombin generation assay (TGA) will be used to assess hypercoagulability, and thromboelastography will be used to assess fibrinolysis. These will be drawn at the time of the thrombotic event.

Secondary Outcome Measures

  1. Exercise Intolerance [Pulmonary embolism patients will undergo this testing at 4-6 weeks after diagnosis. Deep venous thrombosis only patients will undergo testing at 3 months.]

    Participants will undergo Cardiopulmonary Exercise testing to assess maximal aerobic fitness.

  2. Godin Leisure Time Activity Questionnaire [Questionnaire to be filled out to assess activity at baseline, then one month after diagnosis, and 3-6 months after diagnosis.]

    Patients will be asked to fill out a questionnaire to determine levels of physical activity for comparison at different time points throughout treatment.

  3. Pediatric Venous Quality of Life Questionnaire [Participants will be asked to fill this questionnaires 4 weeks after diagnosis, and 3-6 months after diagnosis.]

    Questionnaire to determine quality of life in various areas including school, leisure time, home, and relationships with peers.

  4. OSA-18 Sleep Apnea Questionnaire [Participants will be asked to fill out this questionnaire at one month post diagnosis.]

    Patients will be asked to complete this questionnaire to assess sleep quality and screen for obstructive sleep apnea.

  5. PHQ-9 Questionnaire [Participants will be asked to fill this questionnaire one month after diagnosis.]

    Participants will fill out this questionnaire to screen for depression.

Eligibility Criteria

Criteria

Ages Eligible for Study:
8 Years to 21 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age 8- ≤ 21 years old AND

  • Lower extremity deep venous thrombosis OR

  • Lower extremity deep venous thrombosis AND pulmonary embolism OR

  • Pulmonary Embolism

Exclusion Criteria:
  • Contraindications to exercise, such as post-surgical patients with cast immobility or fractures

  • Patients unable to follow instructions/commands at baseline due to developmental delay

  • Patients with congenital heart disease and abnormal pulmonary circulation/perfusion

  • Contraindications to undergoing magnetic resonance imaging

Contacts and Locations

Locations

Site City State Country Postal Code
1 UT Southwestern Medical Center / Children's Medical Center Dallas Texas United States 75235

Sponsors and Collaborators

  • University of Texas Southwestern Medical Center

Investigators

  • Principal Investigator: Ayesha Zia, MD, University of Texas Southwestern Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ayesha Zia, Assistant Professor, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier:
NCT04294849
Other Study ID Numbers:
  • STU-2019-1406
First Posted:
Mar 4, 2020
Last Update Posted:
Feb 7, 2022
Last Verified:
Jan 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 7, 2022